Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research report released on Wednesday,Benzinga reports.

Agenus Stock Down 5.1 %

NASDAQ:AGEN opened at $3.57 on Wednesday. The company has a market cap of $83.75 million, a P/E ratio of -0.32 and a beta of 1.27. Agenus has a twelve month low of $2.50 and a twelve month high of $19.69. The business has a 50 day moving average price of $3.17 and a two-hundred day moving average price of $4.94.

Institutional Investors Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in the business. Walleye Capital LLC bought a new position in Agenus in the third quarter valued at approximately $1,003,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Agenus in the 2nd quarter valued at $1,050,000. BNP Paribas Financial Markets increased its stake in shares of Agenus by 2,271.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Agenus during the 2nd quarter worth $614,000. Finally, Geode Capital Management LLC lifted its position in shares of Agenus by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after buying an additional 32,016 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.